和晶科技(300279.SZ)擬收購和晶智能剩餘31.08%股權 明起停牌
格隆匯3月29日丨和晶科技(300279.SZ)公佈,公司擬以發行股份的方式購買安徽高新投新材料產業基金合夥企業(有限合夥)、淮北市成長型中小企業基金有限公司及淮北盛大建設投資有限公司合計持有的無錫和晶智能科技有限公司(簡稱“和晶智能”)31.08%的股權,同時向不超過35名特定對象非公開發行股份募集配套資金不超過5000萬元。公司股票自3月30日上午開市時起開始停牌,預計停牌時間不超過10個交易日。
該次交易前,公司已持有和晶智能68.92%股權;該次交易完成後,和晶智能將成為上市公司的全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.